Synopsis Steroid is the primary pharmacotherapeutic choice for sarcoidosis. However, the use of steroids is not encouraged beyond a specific time frame because of associated toxicites. Furthermore, there is less evidence on the second-line therapy for patients with “corticosteroid-sensitive” sarcoidosis. In this regard, the present study compares the effects of azathioprine (AZA) and methotrexate (MTX) as a second-line treatment option in this particular group of patients with sarcoidosis. This “MedFact” discusses a research study from the journal Chest, “Methotrexate vs. Azathioprine in Second-line Therapy of Sarcoidosis.” Authors : Adriane D. M.
Vorselaars, Wim A. Wuyt, Veronique M. M. Vorselaars, Pieter Zanen, Vera H. What was the need for this study? Evidence is lacking in support of the second-line therapy for “corticosteroid-sensitive” sarcoidosis, owing to the complexity of the…
